Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16986431 | 1.00 | EPHX2 (0.43) | EPHX2MEN1KMT2ATSHRPOLB | |
| SCHEMBL13950680 | 0.86 | TSHR (0.52) | EPHX2MEN1KMT2ATSHRPOLB | |
| SCHEMBL16986426 | 0.86 | EPHX2 (0.40) | EPHX2MEN1KMT2ATSHRPOLB | |
| SCHEMBL15297038 | 0.86 | EPHX2 (0.40) | EPHX2MEN1KMT2ATSHRPOLB | |
| SCHEMBL254189 | 0.84 | EPHX1 (0.46) | EPHX2MEN1KMT2ATSHRPOLB | |
| SCHEMBL31050194 | 0.83 | ACHE (0.50) | EPHX2TSHR | |
| SCHEMBL12568734 | 0.81 | ALDH1A1 (0.31) | EPHX2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL28051385 | 0.81 | ACHE (0.42) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15267575 | 0.80 | EPHX2 (0.48) | EPHX2MEN1KMT2ATSHRPOLB | |
| SCHEMBL30784617 | 0.80 | EPHX1 (0.37) | EPHX2TSHRPOLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9028880-B2 | Silica nanoparticle agent conjugates | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130274226-A1 | SILICA NANOPARTICLE AGENT CONJUGATES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-10-17 | — | — | US | disclosed |
| EP-2646818-A2 | SILICA NANOPARTICLE AGENT CONJUGATES | The Board of Trustees of the University of Illionis (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075087-A2 | SILICA NANOPARTICLE AGENT CONJUGATES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274226-A1 | SILICA NANOPARTICLE AGENT CONJUGATES | TST, NCL, MSN | EPHX2 1101/4885MEN1 3680/4885KMT2A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.